Table of Contents 1 Myelodysplastic Syndrome (MDS) Treatment Market Overview 1.1 Product Overview and Scope of Myelodysplastic Syndrome (MDS) Treatment 1.2 Myelodysplastic Syndrome (MDS) Treatment Segment by Type 1.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 Azacitidine 1.2.3 Lenalidomide 1.2.4 Decitabine 1.2.5 Deferasirox 1.3 Myelodysplastic Syndrome (MDS) Treatment Segment by Application 1.3.1 Myelodysplastic Syndrome (MDS) Treatment Sales Comparison by Application: 2020 VS 2026 1.3.2 Refractory cytopenia with unilineage dysplasia 1.3.3 Refractory anemia with ringed sideroblasts 1.3.4 Others 1.4 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Estimates and Forecasts 1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue 2015-2026 1.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales 2015-2026 1.4.3 Myelodysplastic Syndrome (MDS) Treatment Market Size by Region: 2020 Versus 2026 2 Global Myelodysplastic Syndrome (MDS) Treatment Market Competition by Manufacturers 2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturers (2015-2020) 2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2015-2020) 2.3 Global Myelodysplastic Syndrome (MDS) Treatment Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Myelodysplastic Syndrome (MDS) Treatment Manufacturing Sites, Area Served, Product Type 2.5 Myelodysplastic Syndrome (MDS) Treatment Market Competitive Situation and Trends 2.5.1 Myelodysplastic Syndrome (MDS) Treatment Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Myelodysplastic Syndrome (MDS) Treatment Players (Opinion Leaders) 3 Myelodysplastic Syndrome (MDS) Treatment Retrospective Market Scenario by Region 3.1 Global Myelodysplastic Syndrome (MDS) Treatment Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Myelodysplastic Syndrome (MDS) Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Myelodysplastic Syndrome (MDS) Treatment Market Facts & Figures by Country 3.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.3.2 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Myelodysplastic Syndrome (MDS) Treatment Market Facts & Figures by Country 3.4.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.4.2 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Facts & Figures by Region 3.5.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region 3.5.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Facts & Figures by Country 3.6.1 Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.6.2 Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Facts & Figures by Country 3.7.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.7.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Myelodysplastic Syndrome (MDS) Treatment Historic Market Analysis by Type 4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2015-2020) 4.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2015-2020) 4.3 Global Myelodysplastic Syndrome (MDS) Treatment Price Market Share by Type (2015-2020) 4.4 Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Myelodysplastic Syndrome (MDS) Treatment Historic Market Analysis by Application 5.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2015-2020) 5.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2015-2020) 5.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Application (2015-2020) 6 Company Profiles and Key Figures in Myelodysplastic Syndrome (MDS) Treatment Business 6.1 Novartis AG 6.1.1 Corporation Information 6.1.2 Novartis AG Description, Business Overview and Total Revenue 6.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Novartis AG Products Offered 6.1.5 Novartis AG Recent Development 6.2 Celgene Corporation 6.2.1 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.2.2 Celgene Corporation Description, Business Overview and Total Revenue 6.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Celgene Corporation Products Offered 6.2.5 Celgene Corporation Recent Development 6.3 Otsuka Pharmaceutical Co., Ltd 6.3.1 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.3.2 Otsuka Pharmaceutical Co., Ltd Description, Business Overview and Total Revenue 6.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Otsuka Pharmaceutical Co., Ltd Products Offered 6.3.5 Otsuka Pharmaceutical Co., Ltd Recent Development 6.4 Sandoz Inc 6.4.1 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.4.2 Sandoz Inc Description, Business Overview and Total Revenue 6.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Sandoz Inc Products Offered 6.4.5 Sandoz Inc Recent Development 6.5 Dr Reddys Laboratories Limited 6.5.1 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.5.2 Dr Reddys Laboratories Limited Description, Business Overview and Total Revenue 6.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Dr Reddys Laboratories Limited Products Offered 6.5.5 Dr Reddys Laboratories Limited Recent Development 6.6 Pharmascience Inc 6.6.1 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.6.2 Pharmascience Inc Description, Business Overview and Total Revenue 6.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Pharmascience Inc Products Offered 6.6.5 Pharmascience Inc Recent Development 6.7 Accord Healthcare Ltd 6.6.1 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.6.2 Accord Healthcare Ltd Description, Business Overview and Total Revenue 6.6.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Accord Healthcare Ltd Products Offered 6.7.5 Accord Healthcare Ltd Recent Development 6.8 Mylan N.V. 6.8.1 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served 6.8.2 Mylan N.V. Description, Business Overview and Total Revenue 6.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Mylan N.V. Products Offered 6.8.5 Mylan N.V. Recent Development 7 Myelodysplastic Syndrome (MDS) Treatment Manufacturing Cost Analysis 7.1 Myelodysplastic Syndrome (MDS) Treatment Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Treatment 7.4 Myelodysplastic Syndrome (MDS) Treatment Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Myelodysplastic Syndrome (MDS) Treatment Distributors List 8.3 Myelodysplastic Syndrome (MDS) Treatment Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porter's Five Forces Analysis 10 Global Market Forecast 10.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Myelodysplastic Syndrome (MDS) Treatment by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Myelodysplastic Syndrome (MDS) Treatment by Type (2021-2026) 10.2 Myelodysplastic Syndrome (MDS) Treatment Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Myelodysplastic Syndrome (MDS) Treatment by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Myelodysplastic Syndrome (MDS) Treatment by Application (2021-2026) 10.3 Myelodysplastic Syndrome (MDS) Treatment Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Myelodysplastic Syndrome (MDS) Treatment by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Myelodysplastic Syndrome (MDS) Treatment by Region (2021-2026) 10.4 North America Myelodysplastic Syndrome (MDS) Treatment Estimates and Projections (2021-2026) 10.5 Europe Myelodysplastic Syndrome (MDS) Treatment Estimates and Projections (2021-2026) 10.6 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Estimates and Projections (2021-2026) 10.7 Latin America Myelodysplastic Syndrome (MDS) Treatment Estimates and Projections (2021-2026) 10.8 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) Growth Rate Comparison by Type (2015-2026) Table 2. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) Comparison by Application: 2020 VS 2026 Table 3. Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Type (K Units) (US$ Million) (2020 VS 2026) Table 4. Global Key Myelodysplastic Syndrome (MDS) Treatment Manufacturers Covered in This Study Table 5. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) by Manufacturers (2015-2020) Table 6. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Manufacturers (2015-2020) Table 7. Global Myelodysplastic Syndrome (MDS) Treatment Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Myelodysplastic Syndrome (MDS) Treatment Average Price (USD/Unit) of Key Manufacturers (2015-2020) Table 10. Manufacturers Myelodysplastic Syndrome (MDS) Treatment Sales Sites and Area Served Table 11. Manufacturers Myelodysplastic Syndrome (MDS) Treatment Product Types Table 12. Global Myelodysplastic Syndrome (MDS) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Myelodysplastic Syndrome (MDS) Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome (MDS) Treatment as of 2019) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Myelodysplastic Syndrome (MDS) Treatment Players Table 16. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) by Region (2015-2020) Table 17. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2015-2020) Table 18. Global Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) by Region (2015-2020) Table 19. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2015-2020) Table 20. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2015-2020) (K Units) Table 21. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2015-2020) Table 22. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2015-2020) (US$ Million) Table 23. North America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2015-2020) Table 24. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2015-2020) (K Units) Table 25. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2015-2020) Table 26. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2015-2020) (K Units) Table 29. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2015-2020) Table 32. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2015-2020) (K Units) Table 33. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2015-2020) Table 34. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2015-2020) (K Units) Table 37. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2015-2020) Table 40. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) by Type (2015-2020) Table 41. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Type (2015-2020) Table 42. Global Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) by Type (2015-2020) Table 43. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Type (2015-2020) Table 44. Global Myelodysplastic Syndrome (MDS) Treatment Price (USD/Unit) by Type (2015-2020) Table 45. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) by Application (2015-2020) Table 46. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2015-2020) Table 47. Global Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate by Application (2015-2020) Table 48. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 49. Novartis AG Description and Business Overview Table 50. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 51. Novartis AG Main Product Table 52. Novartis AG Recent Development Table 53. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 54. Celgene Corporation Corporation Information Table 55. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 56. Celgene Corporation Main Product Table 57. Celgene Corporation Recent Development Table 58. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 59. Otsuka Pharmaceutical Co., Ltd Corporation Information Table 60. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 61. Otsuka Pharmaceutical Co., Ltd Main Product Table 62. Otsuka Pharmaceutical Co., Ltd Recent Development Table 63. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 64. Sandoz Inc Corporation Information Table 65. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 66. Sandoz Inc Main Product Table 67. Sandoz Inc Recent Development Table 68. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 69. Dr Reddys Laboratories Limited Corporation Information Table 70. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 71. Dr Reddys Laboratories Limited Main Product Table 72. Dr Reddys Laboratories Limited Recent Development Table 73. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 74. Pharmascience Inc Corporation Information Table 75. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 76. Pharmascience Inc Main Product Table 77. Pharmascience Inc Recent Development Table 78. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 79. Accord Healthcare Ltd Corporation Information Table 80. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 81. Accord Healthcare Ltd Main Product Table 82. Accord Healthcare Ltd Recent Development Table 83. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Corporation Information Table 84. Mylan N.V. Corporation Information Table 85. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 86. Mylan N.V. Main Product Table 87. Mylan N.V. Recent Development Table 88. Sales Base and Market Concentration Rate of Raw Material Table 89. Key Suppliers of Raw Materials Table 90. Myelodysplastic Syndrome (MDS) Treatment Distributors List Table 91. Myelodysplastic Syndrome (MDS) Treatment Customers List Table 92. Market Key Trends Table 93. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 94. Key Challenges Table 95. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) Forecast by Type (2021-2026) Table 96. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share Forecast by Type (2021-2026) Table 97. Global Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) Forecast by Type (2021-2026) Table 98. Global Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 99. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) Forecast by Application (2021-2026) Table 100. Global Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) Forecast by Application (2021-2026) Table 101. Global Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) Forecast by Region (2021-2026) Table 102. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share Forecast by Region (2021-2026) Table 103. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Region (2021-2026) (US$ Million) Table 104. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share Forecast by Region (2021-2026) Table 105. Research Programs/Design for This Report Table 106. Key Data Information from Secondary Sources Table 107. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Myelodysplastic Syndrome (MDS) Treatment Figure 2. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type: 2020 VS 2026 Figure 3. Azacitidine Product Picture Figure 4. Lenalidomide Product Picture Figure 5. Decitabine Product Picture Figure 6. Deferasirox Product Picture Figure 7. Global Myelodysplastic Syndrome (MDS) Treatment Consumption Market Share by Application: 2020 VS 2026 Figure 8. Refractory cytopenia with unilineage dysplasia Figure 9. Refractory anemia with ringed sideroblasts Figure 10. Others Figure 11. Global Myelodysplastic Syndrome (MDS) Treatment Market Size 2015-2026 (US$ Million) Figure 12. Global Myelodysplastic Syndrome (MDS) Treatment Sales Capacity (K Units) (2015-2026) Figure 13. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Market Share by Region: 2020 Versus 2026 Figure 14. Myelodysplastic Syndrome (MDS) Treatment Sales Share by Manufacturers in 2020 Figure 15. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers in 2019 Figure 16. The Global 5 and 10 Largest Players: Market Share by Myelodysplastic Syndrome (MDS) Treatment Revenue in 2019 Figure 17. Myelodysplastic Syndrome (MDS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 18. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2015-2020) Figure 19. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region in 2019 Figure 20. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2015-2020) Figure 21. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region in 2019 Figure 22. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country in 2019 Figure 23. North America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country in 2019 Figure 24. U.S. Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 25. U.S. Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 26. Canada Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 27. Canada Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 28. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country in 2019 Figure 29. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country in 2019 Figure 30. Germany Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 31. Germany Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 32. France Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 33. France Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 34. U.K. Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 35. U.K. Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 36. Italy Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 37. Italy Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 38. Russia Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 39. Russia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 40. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region in 2019 Figure 41. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region in 2019 Figure 42. China Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 43. China Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 44. Japan Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 45. Japan Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. South Korea Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 47. South Korea Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. India Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 49. India Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Australia Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 51. Australia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Taiwan Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 53. Taiwan Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. Indonesia Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 55. Indonesia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 56. Thailand Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 57. Thailand Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. Malaysia Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 59. Malaysia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Philippines Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 61. Philippines Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Vietnam Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 63. Vietnam Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 64. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country in 2019 Figure 65. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country in 2019 Figure 66. Mexico Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 67. Mexico Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Brazil Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 69. Brazil Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. Argentina Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 71. Argentina Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country in 2019 Figure 73. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country in 2019 Figure 74. Turkey Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 75. Turkey Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 77. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. U.A.E Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate (2015-2020) (K Units) Figure 79. U.A.E Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Sales Market Share of Myelodysplastic Syndrome (MDS) Treatment by Type (2015-2020) Figure 81. Sales Market Share of Myelodysplastic Syndrome (MDS) Treatment by Type in 2019 Figure 82. Revenue Share of Myelodysplastic Syndrome (MDS) Treatment by Type (2015-2020) Figure 83. Revenue Market Share of Myelodysplastic Syndrome (MDS) Treatment by Type in 2019 Figure 84. Global Myelodysplastic Syndrome (MDS) Treatment Sales Growth by Type (2015-2020) (K Units) Figure 85. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2015-2020) Figure 86. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application in 2019 Figure 87. Global Revenue Share of Myelodysplastic Syndrome (MDS) Treatment by Application (2015-2020) Figure 88. Global Revenue Share of Myelodysplastic Syndrome (MDS) Treatment by Application in 2020 Figure 89. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 90. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018 Figure 91. Otsuka Pharmaceutical Co., Ltd Total Revenue (US$ Million): 2019 Compared with 2018 Figure 92. Sandoz Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 93. Dr Reddys Laboratories Limited Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Pharmascience Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. Accord Healthcare Ltd Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Mylan N.V. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. Price Trend of Key Raw Materials Figure 98. Manufacturing Cost Structure of Myelodysplastic Syndrome (MDS) Treatment Figure 99. Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Treatment Figure 100. Myelodysplastic Syndrome (MDS) Treatment Industrial Chain Analysis Figure 101. Channels of Distribution Figure 102. Distributors Profiles Figure 103. Porter's Five Forces Analysis Figure 104. North America Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 105. North America Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 106. Europe Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 107. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 108. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 109. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 110. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 111. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 112. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 113. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 114. Bottom-up and Top-down Approaches for This Report Figure 115. Data Triangulation Figure 116. Key Executives Interviewed

Novartis AG Celgene Corporation Otsuka Pharmaceutical Co., Ltd Sandoz Inc Dr Reddys Laboratories Limited Pharmascience Inc Accord Healthcare Ltd Mylan N.V.